Modulation of Striatal Adenosinergic Function by HTL0041178, a Selective GPR52 Agonist

April 2022

"By Cliona MacSweeney | Apr 20, 2022

Cliona MacSweeney, a project director in our Translational Medicine department, recently presented this important pre-clinical work at SIRS2022 confirming the ability of the highly selective novel GPR52 agonist HTL00411718 to modulate centrally mediated locomotor activity in response to A2A receptor antagonists. This work highlights an important interplay between the adenosinergic and dopaminergic systems and suggests the potential for GPR52 agonists to control neuropsychiatric symptoms in conditions such as schizophrenia. "

Read more at the source

#DrGPCR #GPCR #IndustryNews